Article Sidebar

Download
PDF
Statistic
Read Counter : 179 Download : 165

Main Article Content

Abstract

The present study was aimed efficiency to evaluate the unsaturated fatty acid omega-3 in reducing the side effects that resulted from the administration of cyclosporine drug in white rabbits. (60) white males' rabbits were used in this study, divided into four groups contain (15) rabbits per group and its subdivision into three groups (5) rabbits per group. The first group is orally administered with normal saline, the second group was administered cyclosporine (25mg/kg) only. Third groups were administered cyclosporine on the first day and omega-3 (500mg/kg) on the second day, while Fourth groups were administered cyclosporine on the first day and omega-3 (1000mg/kg) on the second day for periods (21,30,60) days respectively. After ending study periods, the animals were sacrificed and the blood was collected and the results were shown the following:  Administration with cyclosporine (25mg/kg)only and for periods were led to a significant increase(P<0.05) in total cholesterol, triglycerides and low-density lipoprotein(LDL) and a significant decrease(P<0.05) in high-density lipoprotein(HDL).whereas interaction with (500&1000mg/kg) of omega-3 and to all periods showed a significant decrease (p<0.05) in the total cholesterol, triglycerides and low-density lipoprotein(LDL) and significant decrease(p<0.05) in high-density lipoprotein(HDL), while the non-significant difference in high-density lipoprotein(HDL). This study concluded that omega-3 has an important role in reducing biochemistry side effects that result from the administration of cyclosporine drugs in white rabbits.

Keywords

Cyclosporine omega-3 High density lipoprotein Low density lipoprotein

Article Details

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

How to Cite
Jawad, M. M. (2021). Effect of Unsaturated Fatty Acid Omega-3 on Some Biochemical Criteria in White New Zealand Rabbits Administrated with Cyclosporine Drug. Medical Science Journal for Advance Research, 2(1), 15–24. https://doi.org/10.46966/msjar.v2i1.14
Crossref
Scopus
Google Scholar
Europe PMC

References

  1. Ballantyne CM, Podet EJ. Patsch WP. et at (1989).: Effects of cyclosporine therapy on plasma lipoprotein levels. JAMA; 262:53-56.
  2. Bistrup C, Nielsen FT, Jeppesen VE, Dieperink H (2001). Effect of grapefruit juice on Sandimmun Neoral absorption among stable renal allograft recipients.Nephrol Dial Transplant, 16: 373-377.
  3. Bradley, G., and Ling, V (1994). P-glycoprotein, multidrug resistance and tumor progression.Cancer Metastasis Rev., 13: 223–233.
  4. Borel J.F. (1989). The cyclosporins. Transplant. Proc. 21, 810-815.
  5. Brouwer IA, Katan MB, Zock PL (2004). Dietary alpha-linolenic acid is associated with reduced risk of fatal coronary heart disease, but increased prostate cancer risk: a meta-analysis. J. Nutr.,134, 919-22.
  6. Brown JH, Anwar R, Short CD, et at. (1993).: Serum lipoprotein(a) in renal transplant recipients receiving cyclosponfl monotherapy.Nephrol Dial Transplant;8:863-867.
  7. Crespo-Leiro MG (2005). Calcineurin inhibitors in heart transplantation. Transplantation proceedings; 37(9): Nov.
  8. Cantarovich M, Barkun J, Giannetti N, Cecere R, Besner JG, Tchervenkov J (2004). History of C2 monitoring in heart and liver transplant patients treated with cyclosporine microemulsion.Transplant Proc; 36(2 Suppl):442S-447S.
  9. Diasio RB and Lobuglio AF (1996). Immunomodulators: Immunosuppressive agents and immunostimulants, cited in, Goodman & Gillman's. The pharmacological basis of therapeutics; 9th ed.: 1269 - 1299.
  10. Edwards B.D,Bhatnagar D,Mackness M.L,Gokal R.(2005).Effect of low-dose cyclosporine on plasma loipoproteins and markers of cholestasis inn patients with psoriasis.QIM,88(2):109-113.
  11. Ettinger WH, Hazzard WR. (l988). Prednisone increases very low-density lipoprotein and high-density lipoprotein in healthy men. Metabolism;37: 1055-1058.
  12. Gesch, C.B., Hammond, S.M., Hampson S.E., Eves, and Crowder M.J. (2002)."Influence of supplementary vitamins, minerals and essential fatty acids on the antisocial behaviour of young adult prisoners. Randomised, placebo-controlled trial". The British Journal of Psychiatry: The Journal of Mental Science181: 22-8.
  13. Guillote N., Calzada C.,Colas R. and Guichardant M.(2010).Subgram daily supplementation with DHA protects low-density Lipoprotein from Oxidation in healthy men.Atherosclerossis;208:467-472.
  14. Harris WS, Mozaffarian D, Rimm E, Kris-Etherton P, Rudel LL, Appel LJ, Engler MM, Engler MB,Sacks F(2009). Omega-6 fatty acids and risk for cardiovascular disease: a science advisory from the American Heart Association Nutrition Subcommittee of the Council on Nutrition, Physical Activity, and Metabolism; Council on Cardiovascular Nursing; and Council on Epidemiology and Prevention. Circulation.119, 902-7.
  15. Hayes KC. (2000). Dietary fatty acids, cholesterol, and the lipoprotein profile. Br. J. Nutr. 84,397-9.
  16. Holt DW. (2002). Therapeutic drug monitoring of immunosuppressive drugs in kidney transplan¬tation. Curr Opin Nephrol Hypertens;11 (6):657-63.
  17. Hong S, Gronert K, Devchand PR, et al (2003). Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells. Autacoids in antiinflammation.J Biol Chem;278:14677-87.
  18. Hricik DE, Mayes JT, Schulak JA. (1991). Independent effects of cyclosporine and prednisone on posttransplanthypercholesterolemia. Am J Kidney Dis; 18:353-358.
  19. John GT, Dakshinamurthy DS, Jeyaseelan L, Jacob CK. (2000). The effect of cyclosporin A on plasma lipids during the first year after renal transplantation. Jan-Feb;12(1):14-7.
  20. Jones TE, Morris RG, and Mathew TH (1997). Diltiazem-cyclosporine pharmacokinetic interaction-dose-response relationship. Br J Clin Pharmacol.44:499–504.
  21. Kelly P, Kahan BD (2002). Review: metabolism of immunosuppressant drugs.Curr Drug Metab.;3:275–287.
  22. Kris-Etherton, P., Daniels, SR and Eckel,RH.(2001). Summary of the scientific conference on dietary fatty acids and cardiovascular health. Circulation; 103:1034-9.
  23. Kobayashi N, Okubo M, Marumo F, Uchida H, Endo T,Naka.mura H.(1983).Dc novo development of hypercholesterolemia and elevated high-density lipoprotein cholesterol:Apoprotein A-I ratio in patients with chronic renal failure following kidney transplantation.Nephron;35:237-240.
  24. Kuster GM, Drexel H, Blesch JA, et al. (2004). Rela¬tion of cyclosporine blood levels to adverse effects on lipoproteins. Transplantation; 57:1479-83.
  25. Lukas B. Hilbrands, Pierre N.M. Demacker, Andries J. Hoitsma, Anton F.H. Stalenhoef, and Robert A.P.Koene.(1995).The Effects of Cyclosporine and Prednisone on Serum Lipid and (Apo)Liproprotein Levels in Renal Transplant Recipients.Department of Medicine, Division of Nephrology, University Hospital Nijmegen, Nijmegen. The Netherlands.J. Am. Soc. Nephrol; 5:2073-2081.
  26. Markell MS, Freidman EA (1989). Hyperlipidemia after organ transplantation. Am J Med; 87(5N):61N-7N.
  27. Martin DS. (2003). Dietary protein and hypertension: Where do we stand? Nutrition.19, 385-6.
  28. Moulin P, Appel GB, Ginsberg HN, Tall AR. (1992). Increased concentration of plasma cholesteryl ester transfer protein in nephrotic syndrome: role in dyslipidemia. J Lipid Res; 33:1817-1822.
  29. Mori T.A., Burke V.,Puddey I.B.,Watts G.F. and Beilin L.J.(2000).Purified EPA and DHA have differential Lipids and Lipoproteins,LDL Particle size,glycoseand insulin in mildly hyperlipidemic men.AM J CLINN Nutr;71:1085-1094.
  30. Moyad, M. A. (2005). An introduction to dietary/supplemental omega-3 fatty acids for general health and prevention: part I. Urol.Oncol. 23: 28-35.
  31. Mozaffarian D, Micha R, Wallace S. (2010). Effects on coronary heart disease of increasing polyunsaturated fat in place of saturated fat: a systematic review and meta-analysis of randomized controlled trials. PLoS Med.7, 10-252.
  32. Murtadha M.Jawad AL-khafaji Arshad Noory AL-Dujaily (2014) ‘Effect of unsaturated fatty acid Omega-3 on some Hormonal criteria in White rabbits administrated with cyclosporine drug’, Magazin of Al-Kufa University for Biology, 6(3), pp. 182–189.
  33. Pawlosky, R., Hibbeln, J., Lin, Y. (2003). n-3 fatty acid metabolism in women. Br.J.Nutr. 90: 993-994.
  34. Pichard L, Fabre I, Fabre G, Domergue J, Saint Aubert B, Mourad G, and Maurel P (1990). Cyclosporin A drug interactions. Screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes.Drug Metab Dispos.18:595–606.
  35. Ramsden CE, Hibbeln JR, Majchrzak SF, Davis JM. (2010). n-6 Fatty acid-specific and mixed polyunsaturate dietary interventions have different effects on CHD risk: a meta-analysis of randomised controlled trials. Br. J. Nutr.104, 1586-600.
  36. Suleiman B, El Imam M, Elsabigh M, Eltahir K, Eltahir A, Miskeen E. (2009). Lipid profile in post renal transplant patients treated with cyclosporine in Sudan. Saudi J Kidney Dis Transpl; 20:312-7.
  37. Vathsala A, Weinberg RB, Schoenberg L, et al. (1980). Lipid abnormalities in cyclosporine-prednisone-treated renal transplant recipients.Transplantation 1980;48:37-43.
  38. Webb AT, Plant M, Reaveley DA, et at. (1992). Lipid and lipoprotein (a) concentrations in renal transplant patients.Nephrol Dial Transplant;7:636-64 1.
  39. Webb AT, Reaveley DA, O’Donnel M, O’Connor B, Seed M, Brown EA. (1993). Does cyclosporin increase lipoprotein(a) concentrations in renal transplant recipients? Lancet;34 1:268-270.